title: [Influence of antitumor system rhenium-platinum on biochemical state of the liver].
abstract: Influence of the antitumour rhenium-platinum system on biochemical liver characteristics in the model of tumor growth (Guerin carcinoma) was studied and possible hepatoprotective activity of rhenium cluster compounds when introducing them in different forms was shown, that was confirmed by decreasing of diagnostic enzymes activity in blood (aminotransferase--AST 6 times and ALT 5.6 times, lactatedehydrogenase 4.9 times, gamma-glutamyltranspeptidase 3.6 times) and normalization of morphological state of the liver cells. The hepatoprotective activity of the cluster rhenium compound with adamanthyl ligands was confirmed in the model of acute toxic hepatitis. Introduction of this compound led to reduction of the concentration of MDA in homogenates of liver tissue (2 times), and in blood plasma (3.8 times); to reduction of levels of diagnostic liver enzymes in blood--AST and ALT 5.8 and 5.5 times respectively in comparison with control group. Some aspects of the mechanism of hepatoprotection were discussed, that included the presence of conjugated systems around the quadrupol rhenium-rhenium bond and alkyl radicals with significant positive inductive effects.
authors: V V
authors: VV
authors: Ivchuk
authors: T M
authors: TM
authors: Polishko
authors: O A
authors: OA
authors: Golichenko
authors: O V
authors: OV
authors: Shtemenko
authors: N I
authors: NI
authors: Shtemenko
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D056831:Coordination Complexes / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000627:therapeutic use; D006651:Histocytochemistry; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008081:Liposomes / Q000008:administration & dosage; D008099:Liver / Q000201:enzymology* / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008315:Malondialdehyde / Q000032:analysis; D010984:Platinum / Q000008:administration & dosage; D020011:Protective Agents / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012211:Rhenium / Q000008:administration & dosage* / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D056831:Coordination Complexes; D008081:Liposomes; D020011:Protective Agents; D010984:Platinum; D008315:Malondialdehyde; D012211:Rhenium; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase